GlycoTherapeutics is a drug development startup committed to overcome the efficacy limitations of current cancer immunotherapies. Less than 50% of individuals with cancer receiving immunotherapy obtain a durable response, which is partly due to glycobiology processes that suppress the immune system. Based on over a decade of research, GlycoTherapeutics’ proprietary solution targets these processes by disrupting the interaction of glycans (sugars) that are responsible for immune evasion. The company was established in 2022 as a spin-off from Radboud University, Nijmegen in the Netherlands and has raised >€1.5 million in non-dilutive funding.